| 摘要 |
The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.; |
| 主权项 |
1. A compound of formula (I), salts, N-oxides, solvates, hydrates, racemates, enantiomers or diastereomers thereof: wherein Z1 and Z2 are each independently selected from C—H, C-halo, C—C1-4alkyl, C—C1-4alkylhalo, C—C1-4alkoxy, C—C1-4alkoxyhalo and N; R1 is selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, halo, C1-4alkylhalo, C1-4 alkoxyhalo, C3-7cycloalkyl, C3-7cycloalkenyl, 5-6-membered heterocyclyl and 5-6 membered heteroaryl and wherein alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl and heteroaryl in each occurrence may be optionally substituted; R2 is H or an optional substituent; R3 is an optionally substituted 6-membered heteroaryl group containing N in the 2-(ortho) ring position with reference to the point of attachment or R3 is an optionally substituted 5-membered heteroaryl group containing N in the ring position adjacent to the point of attachment; R4 is H, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, or C3-7cycloalkyl; R5 in each occurrence is independently H or optionally substituted C1-6alkyl; m represents an integer selected from 0, 1, 2, 3, 4, 5 and 6; and each (CH2) moiety when present may be independently optionally substituted with one or two substituents; and further when m is an integer selected from 1, 2, 3, 4, 5 and 6 then one or more (CH2) may be replaced with O, C═O, NH, optionally substituted NC1-6alkyl, S, S═O or SO2. |
